-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 7, the official website of CDE showed that Biotec TIGIT monoclonal antibody BAT6021 was approved for clinical use
According to Biotech's prospectus, BAT6021 is an afucosylation-modified mAb drug candidate, targeting TIGIT for the treatment of tumors
Biotech's pipeline under development
From: Prospectus
The Insight database shows that there are currently 9 clinical TIGIT-related projects in China
TIGIT target domestic competition details
From the Insight library (http://db.